- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00513877
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
An Open Label Phase II Multicentre Clinical Trial of Single Agent Bortezomib in Patients With Malignant Pleural Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of bortezomib and how well it works in treating patients with malignant pleural mesothelioma.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Assess the clinical efficacy of bortezomib based on the evaluation of objective tumor response rate.
Secondary
- Assess additional clinical efficacy of bortezomib based on the evaluation of time to early disease progression and median overall 2-year survival rate.
- Assess safety and toxicity in these patients.
- Assess quality of life using the Lung Cancer Symptom Score.
OUTLINE: This is a multicenter study. Patients are stratified according to current treatment (first-line vs second-line)
Patients receive bortezomib IV on days 1, 8, 15, and 22. Treatment repeats every 5 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients exhibiting objective response or stable disease by week 20, may continue treatment at the discretion of the investigator until evidence of disease progression.
Quality of life is assessed periodically.
After completion of study treatment, patients are followed for up to 2 years.
PROJECTED ACCRUAL: 57 first-line setting and 54 second-line setting patients will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Ghent, België, B-9000
- Universitair Ziekenhuis Gent
-
-
-
-
-
Cork, Ierland
- Cork University Hospital
-
Dublin, Ierland, 9
- Beaumont Hospital
-
Dublin, Ierland, 7
- Mater Misericordiae University Hospital
-
Dublin, Ierland, 4
- St. Vincent's University Hospital
-
Dublin, Ierland, 24
- Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
-
Dublin, Ierland, 8
- St. James's Hospital
-
Galway, Ierland
- Galway University Hospital
-
-
-
-
-
Amsterdam, Nederland, 1066 BE
- Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
-
-
-
-
England
-
London, England, Verenigd Koninkrijk, EC1A 7BE
- Saint Bartholomew's Hospital
-
Sutton, England, Verenigd Koninkrijk, SM2 5PT
- Royal Marsden - Surrey
-
-
Northern Ireland
-
Belfast, Northern Ireland, Verenigd Koninkrijk, BT9 7BL
- Centre for Cancer Research and Cell Biology at Queen's University Belfast
-
-
Scotland
-
Glasgow, Scotland, Verenigd Koninkrijk, G11 6NT
- Beatson West of Scotland Cancer Centre
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Inclusion criteria:
- Histologically confirmed malignant pleural mesothelioma
Meets 1 of the following criteria for first-line or second-line chemotherapy:
- Patients in the first-line setting must be unsuitable for, cannot access locally, or refuse combination chemotherapy
Patients in the second-line setting must be unsuitable for, cannot access locally, or refuse cytotoxic chemotherapy after failure of a first-line regimen
- Second-line patients may not have received more than 1 prior line of antineoplastic treatment for this cancer
Pleural effusions should be drained before treatment whenever possible
- Talc or tetracycline pleurodesis may be used per standard practice for uncontrollable pleural effusions (recurrent despite regular drainage)
Exclusion criteria:
- Symptomatic or known brain or leptomeningeal metastases
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-2
- Hemoglobin ≥ 10 g/dL
- Neutrophil count ≥ 1,500 mm^3
- Platelet count ≥ 100,000/mm^3
- Creatinine clearance ≥ 30 mL/min
- AST and ALT < 3 times upper limit of normal
- Fertile patients must use effective contraception during study therapy
Exclusion criteria:
- Pregnant or breastfeeding
- History of prior malignant tumor within the past 3 years except for nonmelanoma skin tumor or carcinoma in situ of the cervix
- Patients suitably fit to receive a platinum doublet based chemotherapy (first-line only)
Uncontrolled or severe cardiovascular disease including any of the following:
- Myocardial infarction within the past 6 months
- New York Heart Association class III or IV heart failure
- Uncontrolled angina
- Clinically significant pericardial disease
- Cardiac amyloidosis
- Neuropathy ≥ grade 2 OR grade 1 with pain
- Serious medical (e.g., uncontrolled diabetes, hepatic disease, or infection) or psychiatric illness that would interfere with study participation
- Patients with known HIV or hepatitis B or C infection
PRIOR CONCURRENT THERAPY:
- No prior bortezomib
- No prior extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks before enrollment
- No preplanned surgery or procedures that would interfere with the study
More than 4 weeks since enrollment in another therapeutic clinical trial (i.e., received an experimental drug or used an experimental medical device)
- Concurrent participation in non-treatment studies is allowed provided they do not interfere with participation in this study
No concurrent experimental or antineoplastic agent other than bortezomib
- Medications that may have antineoplastic activity, but are taken for other reasons than specific antineoplastic effect (e.g., megestrol [Megace®], cyclo-oxygenase-2 [COX-2] inhibitors, or bisphosphonates) are allowed
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Bortezomib 1.6mg/m2
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Objective tumor response rate (complete response or partial response) as assessed by modified RECIST criteria
Tijdsspanne: 28 days prior to baseline, at 10 weeks and at end of treatment
|
The objective tumour response rate is a primary endpoint of the study.
This will be a proportion of evaluable subjects who achieve a confirmed CR or PR per modified RECIST guidelines within four cycles (20 weeks) of treatment.
|
28 days prior to baseline, at 10 weeks and at end of treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Time to disease progression
Tijdsspanne: Time to disease progression is measured from first treatment until the date of PD or death whichever is first reported. Subjects who did not progress or die will be censored at the day of their last tumour assessment.
|
Time to disease progression is measured from first treatment until the date of PD or death whichever is first reported. Subjects who did not progress or die will be censored at the day of their last tumour assessment.
|
|
Overall survival
Tijdsspanne: Overall Survival is measured from the date of first treatment to the date of the subject's death. If the subject is alive or the vital status is unknown, the date of death will be censored at the date that the subject is last known to be alive.
|
Overall Survival is measured from the date of first treatment to the date of the subject's death. If the subject is alive or the vital status is unknown, the date of death will be censored at the date that the subject is last known to be alive.
|
|
Safety
Tijdsspanne: The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of the pre-determined normal ranges.
|
The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of the pre-determined normal ranges.
|
|
Quality of life
Tijdsspanne: Week 1, Week 10 and end of treatment
|
Quality of life will be assessed using the Lung Cancer Symptom Score
|
Week 1, Week 10 and end of treatment
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Dean A. Fennell, MD, PhD, Centre for Cancer Research and Cell Biology at Queen's University Belfast
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Neoplasmata
- Longziekten
- Neoplasmata per site
- Neoplasmata, glandulair en epitheel
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Adenoom
- Neoplasmata, mesotheliaal
- Pleurale neoplasmata
- Mesothelioom
- Mesothelioom, kwaadaardig
- Antineoplastische middelen
- Bortezomib
Andere studie-ID-nummers
- 05-10 ICORG
- ICORG-05-10
- EUDRACT-2005-004420-39
- EU-20748
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Kwaadaardig mesothelioom
-
Istituto Clinico HumanitasWervingDISTALE MALIGNANT BILIAIRE OBSTRUCTIEItalië
Klinische onderzoeken op beoordeling van de kwaliteit van leven
-
NLT SpineOnbekendDegeneratieve schijfziekteIsraël
-
Vanderbilt University Medical CenterNational Institute of Mental Health (NIMH)WervingAutisme Spectrum StoornisVerenigde Staten
-
Mazor RoboticsVoltooidOnder rug pijnDuitsland, Israël
-
Vanderbilt University Medical CenterNational Institute of Mental Health (NIMH)WervingAutisme Spectrum StoornisVerenigde Staten
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Voltooid
-
Al-Azhar UniversityWervingCariës | Uitbarsting | Body Mass IndexEgypte
-
Umraniye Education and Research HospitalVoltooidSlaap stoornis | Chirurgie | Obesitas, ernstigKalkoen
-
Ibn Sina HospitalBanon IVF Center Assiut, EgyptVoltooid